Literature DB >> 29498526

Targeted Metabolomics Reveals a Protective Role for Basal PPARα in Cholestasis Induced by α-Naphthylisothiocyanate.

Manyun Dai1, Huiying Hua1, Hante Lin1, Gangming Xu1, Xiaowei Hu1, Fei Li2, Frank J Gonzalez3, Aiming Liu1, Julin Yang4.   

Abstract

α-Naphthylisothiocyanate (ANIT) is an experimental agent used to induce intrahepatic cholestasis. The Ppara-null mouse line is widely employed to explore the physiological and pathological roles of PPARα. However, little is known about how PPARα influences the hepatotoxicity of ANIT. In the present study, wild-type and Ppara-null mice were orally treated with ANIT to induce cholestasis. The serum metabolome of wild-type mice segregated from that of the Ppara-null mice, driven by changes of bile acid (BA) metabolites. Alkaline phosphatase and total BAs were elevated preferentially in Ppara-null mice, which correlated with changes in Cyp7a1, Cyp8b1, Mrp3, Cyp3a11, Cyp2b10, Ugt1a2, and Ugt1a5 genes and showed cross-talk between basal PPARα and potentially adaptive pathways. Il6, Tnfa, and target genes in the STAT3 pathway ( Socs3, Fga, Fgb, and Fgg) were up-regulated in Ppara-null mice but not in wild-type mice. The JNK pathway was activated in both mouse lines, while NF-κB and STAT3 were activated only in Ppara-null mice. These data suggest protection against cholestasis by basal PPARα involves regulation of BA metabolism and inhibition of NF-κB/STAT3 signaling. Considering studies on the protective effects of both basal and activated PPARα, caution should be exercised when one attempts to draw conclusions in which the PPARα is modified by genetic manipulation, fasting, or activation in pharmacological and toxicological studies.

Entities:  

Keywords:  NF-κB; PPARα; STAT3; cholestasis; α-naphthylisothiocyanate

Mesh:

Substances:

Year:  2018        PMID: 29498526      PMCID: PMC6628934          DOI: 10.1021/acs.jproteome.7b00838

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  4 in total

Review 1.  Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  Metabolites       Date:  2020-01-28

2.  PPARα-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling.

Authors:  Huiying Hua; Julin Yang; Hante Lin; Yang Xi; Manyun Dai; Gangming Xu; Fuyan Wang; Lihong Liu; Tingqi Zhao; Jing Huang; Frank J Gonzalez; Aiming Liu
Journal:  J Pharm Pharmacol       Date:  2018-09-25       Impact factor: 3.765

3.  Da-Chai-Hu-Tang Protects From Acute Intrahepatic Cholestasis by Inhibiting Hepatic Inflammation and Bile Accumulation via Activation of PPARα.

Authors:  Shihao Xu; Xi Qiao; Peike Peng; Ziyi Zhu; Yaoting Li; Mengyuan Yu; Long Chen; Yin Cai; Jin Xu; Xinwei Shi; Christopher G Proud; Jianling Xie; Kaikai Shen
Journal:  Front Pharmacol       Date:  2022-03-15       Impact factor: 5.810

Review 4.  PPARα: A potential therapeutic target of cholestasis.

Authors:  Xiaoyin Ye; Tong Zhang; Han Han
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.